

Sosei Appoints David Chiswell as Non-Executive Chairman

Today Sosei Co. Ltd. [4565, Tokyo Stock Exchange MOTHERS index], a leading Japanese biopharmaceutical company, is pleased to announce the appointment of Dr. David Chiswell as Non-Executive Chairman.

David Chiswell was a founder and, from 1996 to 2002, the CEO of Cambridge Antibody Technology (CAT), one of the leading European biotechnology companies. Currently David is Chairman of the UK's BioIndustry Association (BIA). In addition, he is Chairman of Arrow Therapeutics Ltd and a non-executive director of Arakis Ltd. David is also an advisor to a number of private equity funds including Nomura Phase 4 Ventures. His previous experience was gained with Amersham International as well as within research posts at various institutions including the Medical Research Council, UCLA and the Imperial Cancer Research Fund.

Shinichi Tamura, Chief Executive Officer, commented: "We are most delighted that David has agreed to become Chairman of Sosei. As Chairman of the BIA and one of a few successful entrepreneurs in the difficult European biotechnology industry environment, David will provide us with practical guidance from a broad perspective as we face an ambitious challenge for global expansion. We are looking forward to working closely with him to realise our ambition."

David Chiswell, Chairman of Sosei commented: "I am delighted to have been appointed Chairman of Sosei's board. I was attracted to join Sosei's board in December 2003 because Sosei has a unique and ambitious business model to develop into a global biopharmaceutical company by combining its expertise in the Japanese pharmaceutical market and R&D arena with a growing and worldwide panel of partnerships. This has enabled Sosei to develop a broad proprietary pipeline of product candidates with significant marketing rights inside and outside of Japan. Since the IPO in July 2004 Sosei has continued to demonstrate its capacity to deliver on significant milestones. I am looking forward to continuing to play a part in Sosei's future development as it seeks to grow into a global biopharmaceutical company."

- end -

Notes for Editors:

About Sosei Co. Ltd.

Sosei Co. Ltd. founded in 1990 by Shinichi Tamura, the ex-CEO of Genentech Japan, is a leading Japanese biopharmaceutical company with significant expertise in drug development. It enriches its core product pipeline by in-licensing compounds from Western and Japanese companies, by its distinctive Drug Reprofile Platform[®] (DRP[®]) and through new molecular entity (NME) research programmes in collaboration with biopharmaceutical companies and universities both in Japan and the West. Sosei is also developing its own sales and marketing organization in Japan. The company is capitalising on its extensive global network established over the past 10 years in its

successful technology transfer business. For further information about Sosei, please visit www.osei.com.

For further information please contact:

Sosei Co. Ltd. Tokyo Headquarter
Ichiban-cho FS Bldg, 8 Ichiban-cho, Chiyoda-ku, Tokyo 102-0082, Japan
Toshio MIYASHITA, Vice President of Corporate Planning
E-mail: tmiyashita@osei.com
Tel: +81 3 5210 3399
Fax: +81 3 5210 3291

Sosei Co. Ltd. London Office
London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH, UK
John DAFFURN, General Manager
E-mail: jdaffurn@osei.com
Tel: +44 20 76912086
Fax: +44 20 7419 5984